TD Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

TD Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-800	Closed	-$66.4K	–	401
2022 Q3	$50K	Buy	+800	New	+$55.9K	0.01%	164
2022 Q1	–	Sell	-800	Closed	-$86K	–	380
2021 Q4	$86K	Hold	800	–	–	0.01%	136
2021 Q3	$88K	Hold	800	–	–	0.01%	125
2021 Q2	$75K	Hold	800	–	–	0.01%	126
2021 Q1	$74K	Hold	800	–	–	0.01%	117
2020 Q4	$59K	Buy	+800	New	+$59.5K	0.01%	115

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TD Capital Management's HZNP Position: Q4 2022 in Review

TD Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 800 shares — an estimated $66.4K sold.

TD Capital Management first reported a position in HZNP in Q4 2020 and held it in 6 quarters. The position peaked at $88K in Q3 2021. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

TD Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
TD Capital Management sold 800 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $66.4K.
TD Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 6 quarters.
TD Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $88K in Q3 2021.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on TD Capital Management's 13F filing for Q4 2022, filed 15 Feb 2023.